A field note should let another person understand exactly what was observed. In this case the documented offer is Rugiet Daily Boost, meaning daily tadalafil plus DHEA in a cinnamon chew. The review keeps product identity, advertised terms and open questions in separate entries. It is a record of public information, not a report from a patient visit.
Availability: Public product listing; individual eligibility and current prescription require confirmation.
The exact product
The distinguishing observation is a hormone-precursor ingredient alongside tadalafil. Record the full active list and supplied form before summarizing the product as a pill, chew or ED treatment. Those short categories lose information that may matter to a pharmacist. A later prescription can differ from the listing, so keep the advertised record and the dispensed label identifiable. Neither should silently replace the other in a treatment history.
| Provider | Rugiet |
|---|---|
| Listed active ingredients | Tadalafil + DHEA |
| Dosage form | Compounded daily cinnamon chew |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | Rugiet: Daily Boost product information |
Price, supply and payment
The price observation is Complete product plan price not verified. Attach a quantity and billing period only where the source provides them together. Keep any calculated monthly equivalent separate from the actual payment schedule. If the figure is approximate, a starting price or unmatched to a complete plan, preserve that qualifier. A useful financial note shows the limit of the observation instead of making the blank fields look complete.
| Earlier trial | 40 selected men; six months; not a Boost study |
|---|---|
| Later trial | 86 randomized; 79 completed; no significant sexual-function differences |
| Price boundary | Full product-specific plan not verified |
| Different from Hims support product | DHEA is not the zinc/arginine/vitamin formula |
What the research can support
The evidence entry reads: a small favorable 1999 DHEA trial and a later trial without significant sexual-function benefit. The unanswered part is applicability of those studies to the exact Boost preparation. Record the studied population, preparation and outcome before linking research to a commercial product. An abstract can establish what its authors reported while leaving methods unavailable for full appraisal. A provider's own survey belongs in a different category from a randomized comparison; a field note should make that source difference easy to see.
| Evidence boundary | a small favorable 1999 DHEA trial and a later trial without significant sexual-function benefit |
|---|---|
| Not established here | applicability of those studies to the exact Boost preparation |
| Clinical and regulatory references | Reiter et al. (1999): DHEA and erectile dysfunction · Morales et al. (2009): androgens and sexual function · MedlinePlus: Tadalafil · FDA: Compounding and the FDA — questions and answers · DailyMed: Tadalafil prescribing information, including section 5.11 · MedlinePlus: Sildenafil |
Safety questions for the prescriber
Use the medication list as a reconciliation document. It should include nitrate or nitrite use, riociguat, other ED treatments, blood-pressure drugs and relevant medical conditions. Do not mark Rugiet Daily Boost as cleared merely because a prior ED drug was tolerated. The clinician must consider the actual formula and history. Record the instructions received rather than deriving a dose, overlap or switching interval from this review.
| DHEA | A hormone precursor; different studies do not establish the exact combination’s benefits or suitability. |
|---|
Availability and the actual prescription
The access observation is time-specific: Public product listing; individual eligibility and current prescription require confirmation. Distinguish a public catalog entry, a safety-library entry, an account offer and a clinician-approved prescription. They are four different states. If support supplies a clarification, save the date and exact product name. A link that opens successfully proves only that a page is reachable, not that enrollment or dispensing has been verified.
Refills, changes and cancellation
When the plan changes, create a new entry rather than overwriting the old one. Note who advised the change, which prescription it concerns and what happens to the next order. A useful question to carry forward is “What finding supports DHEA in my case, and how will its effects be assessed?” Keep clinical response notes separate from shipment and payment confirmations. This makes it easier to identify an unresolved handoff before a refill proceeds on outdated assumptions.
| Membership | 30- and 90-day membership terms; confirm fees and the complete product invoice. |
|---|---|
| Cancellation terms | Terms specify 72 hours before billing; support mentions 24 hours before processing. |
| Timing distinction | Different deadlines refer to different events; confirm the rule for the selected order. |
| Refund boundary | Processing prevents cancellation; ordinary lack of efficacy, side effects or flavor are not refund grounds. |
| Policy sources | Rugiet: terms and conditions · Rugiet Support: canceling an order or subscription · Rugiet Support: treatment response and refunds · Rugiet Support: membership options and inclusions |
Compare named products
The related reviews serve as cross-references, not endorsements. Compare a named field such as active list, dosage form or payment term and state why the difference matters. Do not infer a matching strength from a similar product name. If a proposed alternative has an unverified current plan, retain that uncertainty in the comparison instead of treating the alternative as immediately obtainable.
Questions to keep with the offer
The final field is the boundary of the investigation. We read the cited documents but did not order Rugiet Daily Boost, inspect a pharmacy, test support or observe clinical outcomes. That boundary belongs in the record as much as the ingredients do. New account or prescribing information can update the practical decision; it does not retroactively turn this public-document review into a firsthand assessment.
| Ask about this formula | What finding supports DHEA in my case, and how will its effects be assessed? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Back to all individual product reviews
Trace the information
Checked October 7, 2026. Provider pages establish advertised claims. Medical sources supply general context; citation does not imply endorsement.
- Rugiet: Daily Boost product informationProvider product page; tadalafil and DHEA combination
- Reiter et al. (1999): DHEA and erectile dysfunctionPrimary placebo-controlled study, 40 selected men; indexed abstract reviewed
- Morales et al. (2009): androgens and sexual functionPrimary randomized study, 86 men; indexed abstract reviewed; no significant sexual-function benefit
- Rugiet: terms and conditionsProvider policy; 72-hour subscription cancellation notice and refund eligibility
- Rugiet Support: canceling an order or subscriptionProvider support; member portal steps and processing restrictions
- Rugiet Support: treatment response and refundsProvider policy; refund exclusions and 24-hour order-change notice
- Rugiet Support: membership options and inclusionsProvider support; plan intervals, shipping, and consultation fees
- MedlinePlus: TadalafilDrug information; standard tadalafil products
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination
- MedlinePlus: SildenafilDrug information; standard sildenafil products